The NSCLC segment accounted for US $21.33 billion in 2024, forecast to $64.92 billion by 2033 at CAGR 11.7%, thanks to rising incidence, personalized medicine, and FDA breakthroughs . https://www.datamintelligence.com/research-report/lung-cancer-treatment-market?dr